Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 5/2022

06.08.2022 | Devices (C. Veltmann, Section Editor)

Complications in Device Therapy: Spectrum, Prevalence, and Management

verfasst von: J. Llewellyn, D. Garner, A. Rao

Erschienen in: Current Heart Failure Reports | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cardiac implantable electronic device implant numbers are continually increasing due to the expanding indications and ageing population. This review explores the complications associated with device therapy and discusses ways to minimise and manage such complications.

Recent Findings

Complications related to device therapy contribute to mortality and morbidity. Recent publications have detailed clear guidelines for appropriate cardiac device selection, as well as consensus documents discussing care quality and optimal implantation techniques. There have also been advances in device technologies that may offer alternative options to patients at high risk of/or already having encountered a complication.

Summary

Adherence to guidelines, appropriate training, and selection of device, in addition to good surgical technique are key in reducing the burden of complications and improving acceptability of device therapy.
Literatur
1.
• Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427–520. This document details the most up-to-date evidence-based recommendations for cardiac pacing and cardiac resynchronisation. It was published alongside the updated heart failure guidelines bringing these closely related fields in line with each other.PubMedCrossRef
2.
Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, et al. A decade of information on the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2017 report from the European Heart Rhythm Association. Europace. 2017;19(suppl_2):ii1–90.PubMedCrossRef
3.
Programme NCA. National Audit of Cardiac Rhythm Management Report 2021. Accessed Online Feburary 2022. 2021.
4.
Chui PW, Wang Y, Ranasinghe I, Mitiku TY, Seto AH, Rosman L, et al. Association of physician specialty with long-term implantable cardioverter-defibrillator complication and reoperations rates. Circ Cardiovasc Qual Outcomes. 2019;12(6): e005374.PubMedPubMedCentralCrossRef
5.
• Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomstrom-Lundqvist C, et al. European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2022;24(1):165–72. This work relates to the development of quality indicators for care for patients undergoing device procedures in order to improve clinical outcomes.PubMedCrossRef
6.
Society BHR. Standards for implementation and follow-up of cardiac rhythm management devices in adults; 2018.
7.
Freeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA. Physician procedure volume and complications of cardioverter-defibrillator implantation. Circulation. 2012;125(1):57–64.PubMedCrossRef
8.
Ellenbogen KA, Hellkamp AS, Wilkoff BL, Camunas JL, Love JC, Hadjis TA, et al. Complications arising after implantation of DDD pacemakers: the MOST experience. Am J Cardiol. 2003;92(6):740–1.PubMedCrossRef
9.
Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35(18):1186–94.PubMedCrossRef
10.
Schuchert A, Muto C, Maounis T, Frank R, Boulogne E, Polauck A, et al. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace. 2013;15(1):71–6.PubMedCrossRef
11.
Dorwarth U, Frey B, Dugas M, Matis T, Fiek M, Schmoeckel M, et al. Transvenous defibrillation leads: high incidence of failure during long-term follow-up. J Cardiovasc Electrophysiol. 2003;14(1):38–43.PubMedCrossRef
12.
Sridhar AR, Yarlagadda V, Yeruva MR, Kanmanthareddy A, Vallakati A, Dawn B, et al. Impact of haematoma after pacemaker and CRT device implantation on hospitalization costs, length of stay, and mortality: a population-based study. Europace. 2015;17(10):1548–54.PubMedCrossRef
13.
Peterson PN, Daugherty SL, Wang Y, Vidaillet HJ, Heidenreich PA, Curtis JP, et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation. 2009;119(8):1078–84.PubMedCrossRef
14.
Armaganijan LV, Toff WD, Nielsen JC, Andersen HR, Connolly SJ, Ellenbogen KA, et al. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol. 2012;35(2):131–4.PubMedCrossRef
15.
Tsai V, Goldstein MK, Hsia HH, Wang Y, Curtis J, Heidenreich PA, et al. Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(5):549–56.PubMedCrossRef
16.
Udo EO, van Hemel NM, Zuithoff NP, Kelder JC, Crommentuijn HA, Koopman-Verhagen AM, et al. Long-term outcome of cardiac pacing in octogenarians and nonagenarians. Europace. 2012;14(4):502–8.PubMedCrossRef
17.
Lim YM, Uhm JS, Kim M, Kim IS, Jin MN, Yu HT, et al. Subclinical cardiac perforation by cardiac implantable electronic device leads detected by cardiac computed tomography. BMC Cardiovasc Disord. 2021;21(1):346.PubMedPubMedCentralCrossRef
18.
Blomstrom-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;41(21):2012–32.PubMedCrossRef
19.
Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation. 2010;122(16):1553–61.PubMedCrossRef
20.
Clementy N, Carion PL, Leotoing L, Lamarsalle L, Wilquin-Bequet F, Brown B, et al. Infections and associated costs following cardiovascular implantable electronic device implantations: a nationwide cohort study. Europace. 2018;20(12):1974–80.PubMedCrossRef
21.
Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace. 2015;17(5):767–77.PubMedCrossRef
22.
Green AR, Leff B, Wang Y, Spatz ES, Masoudi FA, Peterson PN, et al. Geriatric conditions in patients undergoing defibrillator implantation for prevention of sudden cardiac death: prevalence and impact on mortality. Circ Cardiovasc Qual Outcomes. 2016;9(1):23–30.PubMedCrossRef
23.
Ozcan KS, Osmonov D, Altay S, Donmez C, Yildirim E, Turkkan C, et al. Pacemaker implantation complication rates in elderly and young patients. Clin Interv Aging. 2013;8:1051–4.PubMedPubMedCentralCrossRef
24.
Kirkfeldt RE, Johansen JB, Nohr EA, Moller M, Arnsbo P, Nielsen JC. Pneumothorax in cardiac pacing: a population-based cohort study of 28,860 Danish patients. Europace. 2012;14(8):1132–8.PubMedCrossRef
25.
Al-Ahmad A, Natale A, Wang PJ, Daubert JP, Padeletti L. How-to manual for pacemaker and ICD devices : procedures and programming. Hoboken, NJ: John Wiley & Sons Inc; 2018.CrossRef
26.
• Burri H, Starck C, Auricchio A, Biffi M, Burri M, D’Avila A, et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace. 2021;23(7):983–1008. This expert consensus discusses the key aspects of device implantation technique to ensure good outcomes and reduced risk of complication.PubMedCrossRef
27.
Da Costa A, Lelievre H, Kirkorian G, Celard M, Chevalier P, Vandenesch F, et al. Role of the preaxillary flora in pacemaker infections: a prospective study. Circulation. 1998;97(18):1791–5.PubMedCrossRef
28.
Mittal S, Shaw RE, Michel K, Palekar R, Arshad A, Musat D, et al. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm. 2014;11(4):595–601.PubMedCrossRef
29.
Darouiche R, Mosier M, Voigt J. Antibiotics and antiseptics to prevent infection in cardiac rhythm management device implantation surgery. Pacing Clin Electrophysiol. 2012;35(11):1348–60.PubMedCrossRef
30.
Krahn AD, Longtin Y, Philippon F, Birnie DH, Manlucu J, Angaran P, et al. Prevention of arrhythmia device infection trial: the PADIT trial. J Am Coll Cardiol. 2018;72(24):3098–109.PubMedCrossRef
31.
Tarakji KG, Mittal S, Kennergren C, Corey R, Poole JE, Schloss E, et al. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med. 2019;380(20):1895–905.PubMedCrossRef
32.
Mittal S, Wilkoff BL, Kennergren C, Poole JE, Corey R, Bracke FA, et al. The World-wide Randomized Antibiotic Envelope Infection Prevention (WRAP-IT) trial: long-term follow-up. Heart Rhythm. 2020;17(7):1115–22.PubMedCrossRef
33.
Wilkoff BL, Boriani G, Mittal S, Poole JE, Kennergren C, Corey GR, et al. Cost-effectiveness of an antibacterial envelope for cardiac implantable electronic device infection prevention in the US healthcare system from the WRAP-IT trial. Circ Arrhythm Electrophysiol. 2020;13(10): e008503.PubMedPubMedCentralCrossRef
34.
Essebag V, Verma A, Healey JS, Krahn AD, Kalfon E, Coutu B, et al. Clinically significant pocket hematoma increases long-term risk of device infection: Bruise Control Infection Study. J Am Coll Cardiol. 2016;67(11):1300–8.PubMedCrossRef
35.
Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084–93.PubMedCrossRef
36.
Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J. 2018;39(44):3973–9.PubMedCrossRef
37.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–76.PubMedCrossRef
38.
Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AH, Dellinger EP, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med. 2009;360(5):491–9.PubMedCrossRef
39.
Ziacchi M, Massaro G, Angeletti A, Statuto G, Diemberger I, Martignani C, et al. Preoperative checklist to reduce the risk of cardiac implantable electronic device infections. Pacing Clin Electrophysiol. 2022;45(2):262–9.PubMedCrossRef
40.
WHO. Global Guidelines for the Prevention of Surgical Site Infection. WHO Document Production Services. 2016.
41.
Mittal S, Wilkoff BL, Poole JE, Kennergren C, Wright DJ, Berman BJ, et al. Low-temperature electrocautery reduces adverse effects from secondary cardiac implantable electronic device procedures: insights from the WRAP-IT trial. Heart Rhythm. 2021;18(7):1142–50.PubMedCrossRef
42.
Bongiorni MG, Proclemer A, Dobreanu D, Marinskis G, Pison L, Blomstrom-Lundqvist C, et al. Preferred tools and techniques for implantation of cardiac electronic devices in Europe: results of the European Heart Rhythm Association survey. Europace. 2013;15(11):1664–8.PubMedCrossRef
43.
Benz AP, Vamos M, Erath JW, Hohnloser SH. Cephalic vs. subclavian lead implantation in cardiac implantable electronic devices: a systematic review and meta-analysis. Europace. 2019;21(1):121–9.PubMedCrossRef
44.
Sassone B, Valzania C, Laffi M, Virzi S, Luzi M, Task Force on Imaging of the Italian Association of A, et al. Axillary vein access for antiarrhythmic cardiac device implantation: a literature review. J Cardiovasc Med (Hagerstown). 2021;22(4):237–45.
45.
Burri H, Sunthorn H, Dorsaz PA, Shah D. Prospective study of axillary vein puncture with or without contrast venography for pacemaker and defibrillator lead implantation. Pacing Clin Electrophysiol. 2005;28(Suppl 1):S280–3.PubMedCrossRef
46.
Yang F, Kulbak G. A new trick to a routine procedure: taking the fear out of the axillary vein stick using the 35 degrees caudal view. Europace. 2015;17(7):1157–60.PubMedCrossRef
47.
Cano O, Andres A, Alonso P, Osca J, Sancho-Tello MJ, Olague J, et al. Incidence and predictors of clinically relevant cardiac perforation associated with systematic implantation of active-fixation pacing and defibrillation leads: a single-centre experience with over 3800 implanted leads. Europace. 2017;19(1):96–102.PubMed
48.
Luria DM, Feinberg MS, Gurevitz OT, Bar-Lev DS, Granit C, Tanami N, et al. Randomized comparison of J-shaped atrial leads with and without active fixation mechanism. Pacing Clin Electrophysiol. 2007;30(3):412–7.PubMedCrossRef
49.
Hattori M, Naruse Y, Oginosawa Y, Matsue Y, Hanaki Y, Kowase S, et al. Prognostic impact of lead tip position confirmed via computed tomography in patients with right ventricular septal pacing. Heart Rhythm. 2019;16(6):921–7.PubMedCrossRef
50.
Shenthar J, Rai MK, Chakali SS, Pillai V, Delhaas T. Computed tomography validated right ventricular mid-septal lead implantation using right ventricular angiography. J Arrhythm. 2021;37(5):1131–8.PubMedPubMedCentralCrossRef
51.
Osmancik P, Stros P. Close proximity of left anterior descending artery to the right ventricular lead apparently implanted into the mid-septum. Indian Pacing Electrophysiol J. 2014;14(2):83–6.PubMedPubMedCentralCrossRef
52.
Liang JJ, Killu AM, Osborn MJ, Jaffe AS. Pacemaker lead perforation causing hemopericardium eight years after implantation. Indian Heart J. 2013;65(3):331–3.PubMedPubMedCentralCrossRef
53.
Kusumoto FM, Schoenfeld MH, Wilkoff BL, Berul CI, Birgersdotter-Green UM, Carrillo R, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14(12):e503–51.PubMedCrossRef
54.
van Gelder BM, Bracke FA. Current of injury (COI) pattern recorded from catheter delivered active fixation pacing leads. Pacing Clin Electrophysiol. 2008;31(6):786–7; author reply 7.
55.
Henrikson CA, Leng CT, Yuh DD, Brinker JA. Computed tomography to assess possible cardiac lead perforation. Pacing Clin Electrophysiol. 2006;29(5):509–11.PubMedCrossRef
56.
RavAcha M, Rafael A, Keaney JJ, Elitzur Y, Danon A, Shauer A, et al. The management of cardiac implantable electronic device lead perforations: a multicentre study. Europace. 2019;21(6):937–43.CrossRef
57.
Migliore F, Zorzi A, Bertaglia E, Leoni L, Siciliano M, De Lazzari M, et al. Incidence, management, and prevention of right ventricular perforation by pacemaker and implantable cardioverter defibrillator leads. Pacing Clin Electrophysiol. 2014;37(12):1602–9.PubMedCrossRef
58.
Burri H, Starck C. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS)-a role for postoperative ultrasound? Authors’ reply. Europace. 2021.
59.
Bull A FF, Wright D P204 Incidence and outcomes of pneumothorax secondary to cardiac device insertion. Thorax 2021;76:A200–A201.
60.
Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007;116(12):1349–55.PubMedCrossRef
61.
Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, et al. Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol. 2010;55(21):2376–82.PubMedCrossRef
62.
Tarakji KG, Korantzopoulos P, Philippon F, Biffi M, Mittal S, Poole JE, et al. Infectious consequences of hematoma from cardiac implantable electronic device procedures and the role of the antibiotic envelope: A WRAP-IT trial analysis. Heart Rhythm. 2021;18(12):2080–6.PubMedCrossRef
63.
Juneau D, Golfam M, Hazra S, Zuckier LS, Garas S, Redpath C, et al. Positron emission tomography and single-photon emission computed tomography imaging in the diagnosis of cardiac implantable electronic device infection: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2017;10(4).
64.
Bongiorni MG, Kennergren C, Butter C, Deharo JC, Kutarski A, Rinaldi CA, et al. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) registry of transvenous lead extraction outcomes. Eur Heart J. 2017;38(40):2995–3005.PubMedCrossRef
65.
Viganego F, O’Donoghue S, Eldadah Z, Shah MH, Rastogi M, Mazel JA, et al. Effect of early diagnosis and treatment with percutaneous lead extraction on survival in patients with cardiac device infections. Am J Cardiol. 2012;109(10):1466–71.PubMedCrossRef
66.
Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch TJ, Tomassoni GF, et al. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N Engl J Med. 2015;373(12):1125–35.PubMedCrossRef
67.
El-Chami MF, Al-Samadi F, Clementy N, Garweg C, Martinez-Sande JL, Piccini JP, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: a comparison to the investigational study and a transvenous historical control. Heart Rhythm. 2018;15(12):1800–7.PubMedCrossRef
68.
Knops RE, OldeNordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, El-Chami MF, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med. 2020;383(6):526–36.PubMedCrossRef
69.
Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115(19):2474–80.PubMedCrossRef
70.
Rordorf R, Casula M, Pezza L, Fortuni F, Sanzo A, Savastano S, et al. Subcutaneous versus transvenous implantable defibrillator: an updated meta-analysis. Heart Rhythm. 2021;18(3):382–91.PubMedCrossRef
Metadaten
Titel
Complications in Device Therapy: Spectrum, Prevalence, and Management
verfasst von
J. Llewellyn
D. Garner
A. Rao
Publikationsdatum
06.08.2022
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 5/2022
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-022-00563-0

Weitere Artikel der Ausgabe 5/2022

Current Heart Failure Reports 5/2022 Zur Ausgabe

Comorbidities (J. Tromp, Section Editor)

Heart Failure in Chronic Infectious and Inflammatory Conditions: Mechanistic Insights from Clinical Heterogeneity

Focus on the Right Heart (S. Rosenkranz, Section Editor)

Right-Sided Mechanical Circulatory Support – A Hemodynamic Perspective

Comorbidities of Hearth Failure (J. Tromp, Section Editor)

Chronic Chagas Disease—the Potential Role of Reinfections in Cardiomyopathy Pathogenesis

Translational Research in Heart Failure (M. Hoes, Section Editor)

Change of Heart: the Epitranscriptome of Small Non-coding RNAs in Heart Failure

Comorbidities (J. Tromp, Section Editor)

Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach

Biomarkers of Heart Failure (W.H.W. Tang and J. Grodin, Section Editors)

Biomarkers for Myocarditis and Inflammatory Cardiomyopathy

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise